Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. Its proprietary clinical programs in Phase II clinical trial include ARRY-797, a p38 program for Lamin A/C-related dilated cardiomyopathy; and ARRY-502, a CRTh2 antagonist to treat Th2-driven allergic disease. The company?s proprietary programs also comprise Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; and ARRY-614, a p38/Tie2 dual inhibitor for myelodysplastic syndromes. Its partnered clinical programs include various drug candidates, including Binimetinib, an MEK inhibitor for cancer; Selumetinib, an MEK inhibitor for cancer; ASLAN001/ARRY-543, an HER2/EGFR inhibitor for gastric cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; VTX-2337, a toll-like receptor for cancer; and Danoprevir, a Hepatitis C virus protease inhibitor. The company?s partnered clinical program
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-0.71||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||9.82%||Sales Growth - Q/Q||-75.48%||P/E||-10.59|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-2.94%||ROE||-12.23%||ROI||-3.87%|
|Current Ratio||4.38||Quick Ratio||Long Term Debt/Equity||0.71||Debt Ratio||0.9|
|Gross Margin||-7.14%||Operating Margin||-5.45%||Net Profit Margin||-13.45%||Dividend Payout Ratio|
|Cash From Financing Activities||38.85 M||Cash From Investing Activities||12.56 M||Cash From Operating Activities||21.47 M||Gross Profit||-5.54 M|
|Net Profit||58.31 M||Operating Profit||54.47 M||Total Assets||208.44 M||Total Current Assets||196.59 M|
|Total Current Liabilities||44.92 M||Total Debt||107.98 M||Total Liabilities||158.29 M||Total Revenue||6.6 M|
|High 52 week||19.99||Low 52 week||12.59||Last close||16.82||Last change||-2.83%|
|RSI||68.08||Average true range||0.92||Beta||1.32||Volume||2.74 M|
|Simple moving average 20 days||7.82%||Simple moving average 50 days||6.7%||Simple moving average 200 days||8.25%|
|Performance Week||-2.72%||Performance Month||5.32%||Performance Quart||22.24%||Performance Half||-1.41%|
|Performance Year||29.68%||Performance Year-to-date||18.04%||Volatility daily||3.82%||Volatility weekly||8.53%|
|Volatility monthly||17.49%||Volatility yearly||60.59%||Relative Volume||178.42%||Average Volume||2.81 M|
|New High||0.46%||New Low|
2019-03-18 08:00:00 | BRAFTOVI® encorafenib in Combination with MEKTOVI® binimetinib and ERBITUX® cetuximab or panitumumab Recommended by the National Comprehensive Cancer Network® NCCN Guidelines as a Treatment Option for Patients with Advanced BRAF-mutant Colorectal Cancer
2019-03-07 12:18:08 | How Financially Strong Is Array BioPharma Inc. NASDAQ:ARRY?
2019-03-06 07:57:00 | Why Array BioPharma Stock Soared 22.9% in February
2019-03-05 16:05:00 | Array BioPharma to Present at the 39th Annual Cowen Health Care Conference
2019-03-05 14:40:34 | 3 Small Caps Posting Big Gains
2019-03-04 08:35:00 | Recent Analysis Shows Array BioPharma, Nabors Industries, Brinker International, Piedmont Office Realty Trust, Och-Ziff Capital Management Group, and Franklin Street Properties Market Influences — Renewed Outlook, Key Drivers of Growth
2019-02-26 13:34:22 | 5 Stocks Seeing Insider Selling Right Now
2019-02-14 14:02:07 | Zoetis ZTS Beats on Q4 Earnings & Sales, Shares Up
2019-02-08 08:03:13 | See what the IHS Markit Score report has to say about Array Biopharma Inc.
2019-02-07 06:34:11 | Will Array BioPharma Continue to Surge Higher?
2019-02-06 08:40:01 | Array BioPharma ARRY Soars: Stock Adds 11% in Session
2019-02-05 17:01:32 | Edited Transcript of ARRY earnings conference call or presentation 5-Feb-19 2:00pm GMT
2019-02-05 16:19:00 | Array BioPharma Surges as Loss Is Narrower Than Expected
2019-02-05 15:39:00 | Here's What Sent Array BioPharma Soaring 11.3% Today
2019-02-05 14:03:06 | Array Biopharma Inc ARRY Q2 2019 Earnings Conference Call Transcript
2019-02-05 13:14:35 | Boulder biotech firm's skin cancer drugs drive 'strong' second quarter
2019-02-05 10:00:03 | Here's Why Array BioPharma ARRY is a Great Momentum Stock to Buy
2019-02-05 09:52:02 | Array BioPharma ARRY Upgraded to Buy: Here's What You Should Know
2019-02-05 09:15:02 | Array BioPharma ARRY Reports Q2 Loss, Tops Revenue Estimates
2019-02-05 08:12:23 | Array BioPharma: Fiscal 2Q Earnings Snapshot
2019-02-05 08:00:00 | Array BioPharma Reports Financial Results for the Second Quarter of Fiscal 2019
2019-02-03 11:34:00 | Here's Why Array BioPharma Jumped 31% in January
2019-01-30 12:08:52 | Does Array BioPharma Inc.’s NASDAQ:ARRY CEO Pay Compare Well With Peers?
2019-01-29 09:30:02 | Has Array BioPharma ARRY Outpaced Other Medical Stocks This Year?
2019-01-26 08:03:32 | See what the IHS Markit Score report has to say about Array Biopharma Inc.
2019-01-18 07:45:12 | Moving Average Crossover Alert: Array BioPharma
2019-01-17 10:00:03 | What Makes Array BioPharma ARRY a Strong Momentum Stock: Buy Now?
2019-01-15 16:48:00 | Here’s your guide to the upcoming biotechnology takeover wave
2019-01-15 13:42:28 | Analyst: This Biopharma Stock Could Surge 76%
2019-01-15 08:01:58 | See what the IHS Markit Score report has to say about Array Biopharma Inc.
2019-01-15 07:55:00 | Today's Research Reports on Trending Tickers: Array BioPharma and VIVUS
2019-01-14 17:02:00 | Array BioPharma Announces 15.3 Months Median Overall Survival from the Safety Lead-in of the Phase 3 BEACON CRC Trial of the Combination BRAFTOVI®, MEKTOVI® and ERBITUX® in BRAF-Mutant Metastatic Colorectal Cancer
2019-01-14 08:03:01 | See what the IHS Markit Score report has to say about Array Biopharma Inc.
2019-01-09 08:25:00 | Does Eli Lilly's $8 Billion Splurge Make Array BioPharma a Buy Now?
2019-01-09 08:03:10 | See what the IHS Markit Score report has to say about Array Biopharma Inc.
2018-12-26 08:03:56 | See what the IHS Markit Score report has to say about Array Biopharma Inc.
2018-12-21 10:22:21 | Breakeven On The Horizon For Array BioPharma Inc. NASDAQ:ARRY
2018-12-20 16:05:00 | Array BioPharma to Present at the 37th Annual J.P. Morgan Healthcare Conference
2018-12-20 08:04:24 | See what the IHS Markit Score report has to say about Array Biopharma Inc.
2018-12-18 08:04:47 | See what the IHS Markit Score report has to say about Array Biopharma Inc.
2018-12-13 08:04:39 | See what the IHS Markit Score report has to say about Array Biopharma Inc.
2018-12-10 00:38:48 | Is Array Biopharma Inc ARRY A Good Stock To Buy?
2018-12-04 08:06:03 | See what the IHS Markit Score report has to say about Array Biopharma Inc.
2018-11-30 13:53:25 | Analysts Remain Bullish on Array BioPharma Stock